4 completed, 3 active not recruiting, 1 unknown, 1 withdrawn. 9 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 9 | Completed 4, Active not recruiting 3, Unknown 1, Withdrawn 1 |
| Phase 2 | 1 | Withdrawn 1 |
Follow OPIOID: new trials by email Literature Review of OPIOID trials Research Report on OPIOID
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Opioid-Free Pain Control Regiment Following Robotic Radical Prostatectomy Tramadol, Gabapentin, Hydrocodone-Acetaminophen - Radical Prostatectomies | Phase 2 / Phase 3 | Withdrawn | Wake Forest University Health Sciences | 2022-08-01 | 2022-09-06 | |
| Development of Variable Volume Automated Mandatory Boluses for Patient-controlled Epidural Analgesia During Labour Epidural infusion pump, Ropivacaine, Fentanyl - Labor Pain, Breakthrough Pain | Phase 3 | Active not recruiting | KK Women's and Children's Hospital | 197 | 2020-08-11 | 2026-08-14 |
| Opioid Analgesic Reduction Study (OARS) - Pilot OPIOID, NON-OPIOID - Post Operative Pain | Phase 3 | Completed | Rutgers, The State University of New Jersey | 53 | 2020-07-06 | 2023-06-06 |
| Managing Pain and Symptom Burden Caused by Chemotherapy in People With Myeloma or Lymphoma Acupuncture, opioid, Assessments - Multiple Myeloma, Hodgkin Disease | Phase 3 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 299 | 2020-06-30 | 2026-10-09 |
| Study of Efficacy, Safety of Fulranumab Adjunctive Use in OA of Hip or Knee, PAI3001 Placebo, Fulranumab 1 mg, Fulranumab 3 mg - Osteoarthritis, Pain | Phase 3 | Completed | Janssen Research & Development, LLC | 79 | 2015-07-07 | 2017-10-02 |
| Comparison of Regimens MPIB, CIPCEA, PCEA epidural delivery system, Ropivacaine, Fentanyl - Breakthrough Pain | Phase 3 | Active not recruiting | KK Women's and Children's Hospital | 839 | 2015-01-28 | 2026-08-07 |
| Single-arm Study to Assess the Safety of Hydromorphone Hydrochloride by Intrathecal Administration Hydromorphone Hydrochloride, Programmable Implantable pump - Chronic Pain | Phase 3 | Completed | Piramal Critical Care, Ltd. | 364 | 2013-06-01 | 2021-08-25 |
| Safety and Efficacy Study of Hydromorphone Hydrochloride by Intrathecal Administration Hydromorphone Hydrochloride, Programmable Implantable pump - Management of Chronic Pain | Phase 3 | Completed | Piramal Critical Care, Ltd. | 153 | 2013-02-01 | 2021-11-04 |
| Safety of Fentanyl TAIFUN Treatment Fentanyl TAIFUN, Opioid - Breakthrough Cancer Pain | Phase 3 | Unknown | Akela Pharma, Inc. | 500 | 2008-12-01 | 2009-01-14 |
Agnosia (3) · Pain (3) · Breakthrough Pain (2) · Pain, Postoperative (2) · Chronic Pain (1) · Hodgkin Disease (1) · Labor Pain (1) · Lymphoma, Non-Hodgkin (1) · Multiple Myeloma (1) · Osteoarthritis (1)
KK Women's and Children's Hospital (2) · Piramal Critical Care, Ltd. (2) · Akela Pharma, Inc. (1) · Janssen Research & Development, LLC (1) · Memorial Sloan Kettering Cancer Center (1) · Rutgers, The State University of New Jersey (1) · Wake Forest University Health Sciences (1)
United States (6) · Poland (2) · Singapore (2) · Canada (1) · Hungary (1) · New Zealand (1) · United Kingdom (1)
Ban L Sng, FANZCA (1) · Janine Fredericks-Younger, DMD (1) · Jun Mao, MD, MSCE (1) · Ram Pathak, MD (1) · Richard L Rauck, MD (1) · Richard Rauck, MD (1) · Wan Ling Leong, FANZCA (1)